2,4,6-Triiodophenol exhibits a range of bioactivities, primarily related to thyroxine binding and inhibition of TTR-mediated fibrillogenesis. It shows a binding affinity of 384.0 in a competition binding assay against prealbumin, relative to L-T4 (100), and a thyroxine binding constant on human plasma prealbumin of KT4 = 7.39E-7 M-1, with a KPCB value of 0.0000075 M-1. Its KPCB/K352 ratio of 33.8 highlights its competitive effectiveness. In rat liver assays, it has a relative binding affinity for thyroxin binding prealbumin (TBPA) that is 10.15 times that of T4, and for nuclear receptors, it is 0.27 times that of T4. In terms of inhibiting TTR-mediated fibrillogenesis, 2,4,6-Triiodophenol has an IC50 of 3200.0 nM and achieves 80.0% inhibition relative to the control.
Additionally, 2,4,6-Triiodophenol displays significant antimicrobial and antiparasitic activities against Cryptosporidium parvum, achieving between 36.0% to 99.6% growth inhibition in infected HCT8 cells depending on concentration and timing. It also has antiviral properties, inhibiting SARS-CoV-2 induced cytotoxicity in Caco-2 and VERO-6 cells at 10 uM, albeit with variable inhibition rates of -2.63% and 0.15%, respectively. It shows 7.667% inhibition of SARS-CoV-2 3CL-Pro protease at 20µM, suggesting potential efficacy in disrupting viral replication. Lastly, 2,4,6-Triiodophenol displays a moderate inhibitory effect on human HDAC6 enzyme activity, with differing inhibition levels of 29.72% using a commercial peptide substrate and -19.41% with a custom peptide substrate..
Note: Summary generated by AI. Data source: ChEMBL 